Targeting BCL6 in diffuse large B-cell lymphoma: What does this mean for the future treatment?

Expert Review of Hematology

Volumn 6, Issue 4, 2013, Pages 343-345

  Cerchietti, Leandro ^a   Melnick, Ari ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

BCL6; DLCBL; germinal centers; lymphoma genesis; survival checkpoints; targeted therapy; transcriptional repression

Indexed keywords

ANIMALS; ANTINEOPLASTIC AGENTS; DNA-BINDING PROTEINS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICE; MOLECULAR TARGETED THERAPY;

EID: 84894195316     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2013.826928     Document Type: Review

References (19)

1. Basso K, Dalla-Favera R. Roles of BCL6 in normal and transformed germinal center B cells. Immunol. Rev. 247(1), 172-183 (2012).
2. Ranuncolo SM, Polo JM, Dierov J et al. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat. Immunol. 8(7), 705-714 (2007).
3. Phan RT, Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 432(7017), 635-639 (2004).
4. Ci W, Polo JM, Cerchietti L et al. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood 113(22), 5536-5548 (2009).
5. Basso K, Saito M, Sumazin P et al. Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells. Blood 115(5), 975-984 (2010).
6. Lenz G, Staudt LM. Aggressive lymphomas. N. Engl. J. Med. 362(15), 1417-1429 (2010).
7. Polo JM, Dell'oso T, Ranuncolo SM et al. Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nat. Med. 10(12), 1329-1335 (2004).
8. Polo JM, Juszczynski P, Monti S et al. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc. Natl Acad. Sci. USA 104(9), 3207-3212 (2007).
9. Cerchietti LC, Yang SN, Shaknovich R et al. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood 113(15), 3397-3405 (2009).
10. Parekh S, Prive G, Melnick A. Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas. Leuk. Lymphoma 49(5), 874-882 (2008).
11. Barish GD, Yu RT, Karunasiri MS et al. The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis. Cell Metab. 15(4), 554-562 (2012).
12. Huang C, Hatzi K, Melnick A. Lineage-specific functions of Bcl-6 in immunity and inflammation are mediated by distinct biochemical mechanisms. Nat. Immunol. 14(4), 380-388 (2013).
13. Hatzi K, Jiang Y, Garrett-Bakelman et al. A hybrid mechanism of action for BCL6 in B-cells defined by formation of functionally distinct complexes at enhancers and promoters. Cell Rep. (2013) (In Press).
14. Cerchietti LC, Ghetu AF, Zhu X et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 17(4), 400-411 (2010).
15. Cerchietti LC, Polo JM, Da Silva GF et al. Sequential transcription factor targeting for diffuse large B-cell lymphomas. Cancer Res. 68(9), 3361-3369 (2008).
16. Cerchietti LC, Hatzi K, Caldas-Lopes E et al. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. J. Clin. Invest. doi: 10.1172/JCI42869 (2010) (Epub ahead of print).
17. Antun A, Cerchietti L, Aparo S, Shaknovich R, Melnick A. BCL6 Inhibitor Peptide Have Powerful Anti-Lymphoma Activity in Animal Models of Diffuse Large B-Cell Lymphoma and Synergize with Other Anti-Lymphoma Drugs. Blood 108 (ASH Annual Meeting Abstracts)(827) (2006).
18. Dupont T, Dong Z, Yang SN, Melnick A, Cerchietti L. Combinatorial Targeting of BCL6 and Anti-Apoptotic Proteins in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). Blood (ASH annual meeting abstracts) 120(Abstract 64) (2012).
19. Juszczynski P, Chen L, O'donnell E et al. BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase. PTPROt. Blood 114(26), 5315-5321 (2009).